Sci Transl Med:科学家开发出新型“汗水贴纸”,柔软、亲肤且可快速诊断囊性纤维化

2021-04-02 MedSci原创 MedSci原创

一个研究小组开发了一种新型的贴在皮肤上的贴纸,它能吸收汗液然后变色,在几分钟内就能对囊性纤维化做出准确、易于阅读的诊断。

囊性纤维化是最常见的缩短寿命的遗传疾病,在美国每3300个新生儿中就有一个,全世界有7万人患病。患者是否能有良好的结局完全取决于能否早期诊断因为这种疾病会攻击消化系统,如果患者出生后不立即接受治疗,就会严重营养不良。

Pixabay.com

婴儿囊性纤维化的诊断是通过汗液测试进行的,因为汗液中的氯化物浓度升高可表明囊性纤维化。但目前的方法灵敏度较低,需要反复测试。美国西北大学领导的一个研究小组开发了一种新型贴在皮肤上的贴纸,这种贴纸可以吸收汗水然后变色,在几分钟内就能对囊性纤维化做出准确形象的诊断。这种柔软、柔韧、类似皮肤的“汗液贴纸”与目前的诊断技术形成了鲜明对比。

在西北大学研发出这种汗液贴纸后,研究人员在临床试验中对其进行了验证,试验对象包括芝加哥安和罗伯特·H·卢里儿童医院中心的囊性纤维化患者和健康志愿者。结果显示,该贴纸在收集汗液量方面表现出了更高的性能,精确度与传统平台相当。该研究结果于3月31日作为封面专题文章发表在了Science Translational Medicine杂志上。

一般情况下,所有新生儿在出生后的头几天都要通过足跟刺破来检查囊性纤维化。如果检查结果不正常,儿科医生就会要求进行汗液检查以确认诊断。在汗液测试过程中,婴儿必须佩戴这个坚硬的腕带设备长达30分钟。有时较小的婴儿很难产生足够的汗液来进行测试。其他时候,汗液收集装置松动,不合适,无法收集足够大的样本。在这种情况下,婴儿必须在晚些时候再做测试,这就会引起焦虑,延误治疗。

作为Lurie儿童医院临床化学实验室的前任主任,Shannon Haymond教授目睹了太多的这种情况。由于刚性收集装置在小婴儿手臂上的贴合性和密封性差,许多家庭都经历了延迟的结果和诊断。

这种新型毫米厚的贴纸可以直接温和地与皮肤接触,且不需要粗糙的粘合剂。这不仅更舒适,亲密的耦合也使贴纸收集的汗液比目前的临床方法多33%。高采集率确保了一次检测将持续收集足够大的样本,以提供准确的结果。

这款贴纸还内置了比色传感器,可以使用智能手机摄像头实时检测、测量和分析氯化物浓度,省去了昂贵的实验室设备和繁琐的等待时间。这为在家庭环境中进行检测提供了可能性,或许也可以缓解农村或资源匮乏地区的不得不花费高昂的经济代价进入临床中心的情况。

贴纸内传感器概念图

接下来,研究小组认为,这种汗液贴纸可以用于监测囊性纤维化患者的长期健康状况,并衡量他们对治疗的反应。例如,如果标签检测到氯含量的变化,就可以告知医生治疗计划。

“因为这种装置是无约束的,我们计划在临床环境之外使用它,”研究合著者Roozbeh Ghaffari说,他是西北大学生物医学工程研究副教授,也是QSIB转化研究主任。“鉴于这些新的功能和进一步的临床验证,接受治疗的囊性纤维化患者有朝一日可以在家里使用汗水贴纸来追踪他们日常生活中的身体情况。

参考文献:Tyler R. Ray, Maja Ivanovic, Paul M. Curtis, Daniel Franklin, Kerem Guventurk, William J. Jeang, Joseph Chafetz, Hannah Gaertner, Grace Young, Steve Rebollo, Jeffrey B. Model, Stephen P. Lee, John Ciraldo, Jonathan T. Reeder, Aurélie Hourlier-Fargette, Amay J. Bandodkar, Jungil Choi, Alexander J. Aranyosi, Roozbeh Ghaffari, Susanna A. McColley, Shannon Haymond, John A. Rogers. Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and managementScience Translational Medicine, 2021; 13 (587): eabd8109 DOI: 10.1126/scitranslmed.abd8109

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
    2021-09-16 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
    2021-04-02 ms5000001586473032

    便

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
    2021-04-02 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1657425, encodeId=cc61165e425e1, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Thu Sep 16 16:28:46 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067538, encodeId=f7dd206e53875, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Mon Aug 16 21:28:46 CST 2021, time=2021-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1675944, encodeId=23b016e594455, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Thu Jun 24 22:28:46 CST 2021, time=2021-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610982, encodeId=cd1b1610982e8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Apr 04 11:28:46 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953386, encodeId=a60a953386a8, content=便, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbe75476304, createdName=ms5000001586473032, createdTime=Fri Apr 02 22:28:01 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953381, encodeId=04c395338142, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Apr 02 22:11:58 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953376, encodeId=8ece9533e6e7, content=太方便了,大有用处, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=27b52225822, createdName=12111f05m35(暂无昵称), createdTime=Fri Apr 02 21:39:31 CST 2021, time=2021-04-02, status=1, ipAttribution=)]
    2021-04-02 12111f05m35(暂无昵称)

    太方便了,大有用处

    0

相关资讯

Kalydeco在欧盟获准用于治疗囊性纤维化(CF)婴儿

Vertex公司已获得欧盟委员会(EU)的批准,将Kalydeco(ivacaftor)的适应症扩展至包括四个月或更大年龄的患有囊性纤维化(CF)的婴儿。

欧洲委员会批准SYMKEVI联合KALYDECO治疗6-11岁囊性纤维化患儿

欧盟委员会已批准SYMKEVI(tezacaftor / ivacaftor)联合KALYDECO(ivacaftor)的适应症扩展,以包括治疗6-11岁囊性纤维化患儿。

在I / II期研究中,Translate Bio基于mRNA的囊性纤维化疗法失败了

称虽然吸入的mRNA候选药物MRT5005总体上安全且耐受性良好,但未显示出对肺功能的任何益处(以一秒钟强制呼气量表示,ppFEV1)。

Lancet Respir Med:Tezacaftor-iVacaftor治疗携带CFTR Phe508del突变的囊性纤维化患者的长期预后

Tezacaftor-iVacaftor是一种获批的囊性纤维化跨膜电导调节剂(CFTR)调节剂,在为期8-24周的3期临床研究中显示有效,安全性和耐受性良好

FDA授予基因疗法SPIRO-2101“孤儿药称号”,用于治疗囊性纤维化

囊性纤维化(CF)是一种常见的遗传疾病,此病症最常影响肺脏,但也常发生于胰脏、肝脏、肾脏以及肠。长期影响包含肺部感染所导致的呼吸困难以及积痰。

新型反义寡核苷酸药物:临床证实其治疗囊性纤维化的潜力

该研究首次证明通过雾化器直接输送到肺部的反义寡核苷酸药物,可显著降低ENaC信使RNA水平。